ReviewPharmaceutics2024
Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.
Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- JLP-2008 Fixed-Dose Combination Tablet Demonstrates Bioequivalence and Comparable Safety to Separate Dapagliflozin + Pioglitazone in Healthy Participants.European journal of drug metabolism and pharmacokinetics · 2026Trial
- Comparative bioavailability of a novel fixed-dose combination of ticagrelor and acetylsalicylic acid.Clinical pharmacology in drug development · 2026Trial
- Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens forWorld journal of gastroenterology · 2025Trial
- Review
- Neurons Die Not by One Hit, but by Signaling Convergence.Molecular neurobiology · 2026Review
- Orthogonal Chemistry Enables Precision Nanoparticle Cofunctionalization for Tuning Immune Stimulation and Antigen Presentation.Biomacromolecules · 2026Article
- Recent Developments in Ferulic Acid- and Caffeic Acid-Based Hybrids with Potential Anticancer Properties.Molecules (Basel, Switzerland) · 2026Review
- SeSA-HCPT: A dual-targeting agent that induces DNA damage and inhibits repair for castration-resistant prostate cancer therapy.iScience · 2026Article
- Analysis of the utilization and effectiveness of tuberculosis digital adherence technology in southeastern China.Frontiers in public health · 2026Article
- Reductive stress and the role of antioxidants in male infertility: a narrative review.Archives of gynecology and obstetrics · 2025Review
- Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in type 2 diabetes: a nationwide comparative effectiveness study.Cardiovascular diabetology · 2025Observational
- Alfalfa (Medicago sativa) and neurodegeneration: mechanistic insights into oxidative stress, inflammation, and neuronal survival pathways.Molecular biology reports · 2025Review
- Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations.Pharmaceutics · 2025Article
- Physicochemical Properties and Molecular Insights of Favipiravir and Roflumilast Solid Dispersions for COVID-19 Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis.Molecular pharmaceutics · 2025Article
- New Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.AAPS PharmSciTech · 2025Article
- Prospective Utilization of Nanocarriers Loaded with Drug Combination for Treating Alzheimer's Disease.Current pharmaceutical design · 2025Review
- Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases.Journal of cardiovascular development and disease · 2024Article
- Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging.Nanotheranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Whilst monotherapy is traditionally the preferred treatment starting point for chronic conditions such as hypertension and diabetes, other diseases require the use of multiple drugs (polytherapy) from the onset of treatment (e.g., human immunodeficiency virus acquired immunodeficiency syndrome, tuberculosis, and malaria). Successful treatment of these chronic conditions is sometimes hampered by patient non-adherence to polytherapy. The options available for polytherapy are either the sequential addition of individual drug products to deliver an effective multi-drug regimen or the use of a single fixed-dose combination (FDC) therapy product. This article intends to critically review the use of FDC drug therapy and provide an insight into FDC products which are already commercially available. Shortcomings of FDC formulations are discussed from multiple perspectives and research gaps are identified. Moreover, an overview of fundamental formulation considerations is provided to aid formulation scientists in the design and development of new FDC products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.